

SEAGEN INC.

ISIN: US81181C1045

WKN: 81181C104

Asset Class: **Stock**

Company

2022/01/27 18:12:15



Price

123.96

USD

Difference



0.33%(0.41)



Contact Details

SEAGEN INC.

Tel: 1-425-527-4000

--

Fax: -

21823-30th Drive SE

Web: <http://www.seattlegenetics.com>

98021 Bothell

E-mail: contact@seagen.com

Company Profile

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	3,062,384,000		1,176,641,000		653,595,000	
Common stock capital		181,000		172,000		160,000
Fixed assets	938,522,000		1,029,225,000		849,734,000	
Equity capital of a company		3,488,100,000		1,876,287,000		1,273,943,000
Cash and cash equivalents	558,424,000		274,562,000		78,186,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		388,138,000		259,357,000		225,072,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		124,668,000		70,222,000		4,314,000
Different income		-		-		-
Other liabilities		62,784,000		2,615,000		4,314,000
Total assets	4,000,906,000	4,000,906,000	2,205,866,000	2,205,866,000	1,503,329,000	1,503,329,000

Balance notes

	2020	2019	2018
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	2,092	1,605	1,302
Equity ratio	87.18%	85.06%	84.74%
Debt-equity ratio	14.70%	17.57%	18.01%

Others

	2020	2019	2018
Tax Expense Rate	0.33%	0.00%	9.60%

SEAGEN INC.

ISIN: US81181C1045

WKN: 81181C104

Asset Class: Stock

Income statement

	2020	2019	2018
Turnover	2,175,536,000	916,713,000	654,700,000
Net income	613,670,000	-158,650,000	-222,693,000
EBIT	537,327,494	-150,498,785	-223,125,812
Operating income before taxes	615,701,000	-158,650,000	-246,346,000
Cash Flow	867,839,000	-157,077,000	-203,536,000
Net interest income	7,245,000	11,771,000	6,316,000
Research and development expenses	827,129,000	719,374,000	565,309,000
Income taxes	2,031,000	0	-23,653,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	918,363	504,392	444,060

Board of Directors

Members of Management Board

Alpna Seth	Member of Board of Directors
Felix Baker	Member of Board of Directors
Marc Lippman	Member of Board of Directors
Nancy Simonian	Member of Board of Directors
Ted Love	Member of Board of Directors
Daniel Welch	Member of Board of Directors
David Gryska	Member of Board of Directors
John Orwin	Member of Board of Directors
Clay B. Siegall	Chairman of Managing Board
Vaughn B. Himes	Member of Executive Committee
Charles Romp	Member of Executive Committee
Christopher Pawlowicz	Member of Executive Committee
Jean I. Liu	Member of Executive Committee
Natasha Hernday	Member of Executive Committee
Roger D. Dansey, M.D.	Member of Executive Committee
Todd E. Simpson	Member of Executive Committee
Tuomo Pátsi	Member of Executive Committee